8 completed, 1 unknown. 5 Phase 4, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
Follow Purdue Pharma, Canada: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD Foquest - Attention Deficit Hyperactivity Disorder | Phase 4 | Unknown | JPM van Stralen Medicine Professional | 41 | 2020-12-01 | 2023-09-28 |
| Real World Evidence of the Efficacy and Safety of FOQUEST Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate - Attention Deficit-Hyperactivity Disorder | Phase 4 | Completed | Purdue Pharma, Canada | 257 | 2019-09-19 | 2021-09-16 |
| Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Oxycodone Naloxone Combination - Chronic Pain | Phase 4 | Completed | University of British Columbia | 1 | 2019-09-05 | 2021-12-10 |
| A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Methylphenidate Hydrochloride Controlled-Release Capsules, Placebo Capsule - Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder | Phase 4 | Completed | McMaster University | 60 | 2019-04-20 | 2023-10-26 |
| PENTHROX™ in the Canadian Emergency Department (ED) Methoxyflurane 3mL - Pain, Acute | Phase 4 | Completed | Purdue Pharma, Canada | 99 | 2019-04-08 | 2021-09-16 |
| Observational Study on the Use of Akynzeo® in Patients Receiving HEC 300mg netupitant/0.5mg palonosetron hydrochloride - Chemotherapy-Induced Nausea and Vomiting | Completed | Purdue Pharma, Canada | 207 | 2018-10-03 | 2023-08-18 | |
| PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) PRC-063 oral capsules, Placebo oral capsules - ADHD | Phase 3 | Completed | Purdue Pharma, Canada | 288 | 2018-08-21 | 2021-07-26 |
| PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD PRC-063 oral capsules, Placebo oral capsules - ADHD | Phase 3 | Completed | Purdue Pharma, Canada | 156 | 2017-05-01 | 2019-11-05 |
| The Efficacy and Safety of PRC-063 in Adult ADHD Patients Placebo, PRC-063 25 mg, PRC-063 45 mg - ADHD | Phase 3 | Completed | Rhodes Pharmaceuticals, L.P. | 375 | 2014-04-01 | 2019-05-07 |
Attention Deficit Disorder with Hyperactivity (6) · Acute Pain (1) · Agoraphobia (1) · Anxiety Disorders (1) · Chronic Pain (1) · Generalized Anxiety Disorder (1) · Opioid-Induced Constipation (1) · Panic Disorder (1) · Phobia, Social (1) · Spinal Cord Injuries (1) · Vomiting (1)
Lisdexamfetamine Dimesylate (1) · Methoxyflurane (1) · Methylphenidate (1) · netupitant, palosentron drug combination (1) · oxycodone naloxone combination (1)
Canada (7) · United States (3)
Sailaja Bhaskar, PhD (2) · Andrei Krassioukov, MD,PhD,FRCPC (1) · Jodan Ratz, PhD (1) · Joseph Reiz (1) · Judy van Stralen, MD (1) · Michael Van Ameringen, MD, FRCPC (1) · Sonja Dhani, PhD (1)